Skip to Content

Bevespi Aerosphere Approval History

  • FDA approved: Yes (First approved April 25th, 2016)
  • Brand name: Bevespi Aerosphere
  • Generic name: formoterol fumarate and glycopyrrolate
  • Dosage form: Inhalation Aerosol
  • Company: AstraZeneca Pharmaceuticals LP
  • Treatment for: COPD

Bevespi Aerosphere (formoterol fumarate and glycopyrrolate) is a long -acting beta2-adrenergic agonist (LABA) and anticholinergic combination indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

The FDA approval of Bevespi Aerosphere was based on results of the PINNACLE phase III pivotal studies (PINNACLE 1, PINNACLE 2, and a safety extension study, PINNACLE 3) which included over 3,700 patients with moderate to very severe COPD. The studies demonstrated that Bevespi Aerosphere achieved statistically significant improvements in lung function as measured by change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at 24 weeks (p<0.001) versus its individual components (glycopyrrolate 9 mcg and formoterol fumarate 4.8 mcg) and placebo.

Bevespi Aerosphere is administered twice-daily in the morning and in the evening. It is not intended to relieve acute symptoms of COPD, which should be treated with a rescue inhaler such as albuterol.

The most commonly reported side effects include urinary tract infection and cough.

Development History and FDA Approval Process for Bevespi Aerosphere

DateArticle
Apr 25, 2016Approval Bevespi Aerosphere Approved by the FDA for Patients with COPD
Mar 18, 2015AstraZeneca announces positive Phase III top-line results for PT003 from the PINNACLE 1 and PINNACLE 2 studies in COPD
Jan  6, 2012Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide